Jack L Erion

Title: Jack L Erion: Innovator in Peptide Technology

Introduction

Jack L Erion is a notable inventor based in St. Charles, MO (US). He has made significant contributions to the field of peptide technology, holding two patents that focus on neurotensin derivatives and radiolabeled peptide compositions. His work has implications for both diagnostic and therapeutic applications in medicine.

Latest Patents

Erion's latest patents include "Labeled neurotensin derivatives" and "Radiolabeled peptide compositions for site-specific targeting." The first patent discloses peptide analogs of neurotensin that are resistant to enzymatic degradation while retaining high binding affinity for neurotensin receptors. These pharmaceutical compositions are useful for diagnostic and therapeutic purposes. The second patent relates to radiolabeled peptide compositions designed for radiopharmaceutical use. It specifically addresses peptides that have an unmodified carboxy terminal amino acid, which can be coupled to a diagnostic or therapeutic radionuclide by a chelating agent. This innovation allows for targeted biological site applications.

Career Highlights

Throughout his career, Jack L Erion has worked with prominent companies such as Mallinckrodt Medical, Inc. and Biosynthema Inc. His experience in these organizations has contributed to his expertise in peptide technology and its applications in the medical field.

Collaborations

Erion has collaborated with notable professionals in his field, including Ananthachari Srinivasan and Mary Marmion Dyszlewski. These collaborations have likely enriched his research and development efforts.

Conclusion

Jack L Erion's contributions to peptide technology through his patents and career experiences highlight his role as an innovator in the medical field. His work continues to influence diagnostic and therapeutic advancements.